Private company

LUMOS PHARMA, INC.

LUMOS PHARMA, INC. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Austin, Texas.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersAustin, Texas1
  • Incorporated inDE2
  • Business address4200 Marathon Blvd., Suite 200, Austin, Tx 787562
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

The Company entered into a business combination (the “Merger”) between the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). The Merger closed on March 18, 2020, and Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-1785.2%Operating margin5
-1659.4%Net margin5
34.7%Revenue growth, 20235
-124.6%Return on equity5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$22.1M
  • Income tax0¢$29.0K

Out of $2.1M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$2.1M in 2023+426% since 2017
0$1.0M$2.0M$3.0M2017: $390.0K$390.0K20172018: $1.2M$1.2M2018+209%2019: $936.0K$936.0K2019−22%2020: $168.0K$168.0K2020−82%2021: $230.0K$230.0K2021+37%2022: $1.5M$1.5M2022+562%2023: $2.1M$2.1M2023+35%
Operating income69785-$36.6M in 2023−50% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$72.9M-$72.9M20172018: -$62.4M-$62.4M2018−14%2019: -$9.8M-$9.8M2019−84%2020: -$26.3M-$26.3M2020+168%2021: -$31.3M-$31.3M2021+19%2022: -$32.0M-$32.0M2022+2%2023: -$36.6M-$36.6M2023+14%
Net income69785-$34.0M in 2023−53% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$72.0M-$72.0M20172018: -$53.6M-$53.6M2018−26%2019: -$9.7M-$9.7M2019−82%2020: -$5.7M-$5.7M2020−42%2021: -$30.4M-$30.4M2021+437%2022: -$31.1M-$31.1M2022+2%2023: -$34.0M-$34.0M2023+10%
Fiscal year2017201820192020202120222023
Revenue$390.0K6$1.2M6$936.0K6$168.0K7$230.0K8$1.5M5$2.1M5
Research and development$69.9M6$45.7M6$5.7M9$9.2M7$16.2M8$17.9M5$22.1M5
Operating expenses$31.6M8$33.6M5$38.7M5
Operating income-$72.9M6-$62.4M6-$9.8M9-$26.3M7-$31.3M8-$32.0M5-$36.6M5
Interest$119.0K6$52.0K6$50.0K6
Income before tax-$31.1M8-$31.1M5-$34.1M5
Income tax-$559.0K6-$7.0M6$09-$14.0M7-$636.0K8-$13.0K5-$29.0K5
Net income-$72.0M6-$53.6M6-$9.7M9-$5.7M7-$30.4M8-$31.1M5-$34.0M5
Earnings per share-$0.937-$3.658-$3.715-$4.185
Earnings per share (diluted)-$0.937-$3.658-$3.715-$4.185
Shares (weighted, basic)8.3M shares88.4M shares58.1M shares5
Shares (weighted, diluted)8.3M shares88.4M shares58.1M shares5

Compare LUMOS PHARMA, INC. with another company

Corporate structure

LUMOS PHARMA, INC. sits at the top of its group. 5 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of LUMOS PHARMA, INC.

  • Private Advisor Group, LLC Filed SCHEDULE 13G/A on LUMOS PHARMA, INC., latest Feb 13, 2025 (2 filings since Nov 12, 2024)
  • Wells Fargo Filed SCHEDULE 13G/A on LUMOS PHARMA, INC., latest Oct 25, 2024 (2 filings since Feb 6, 2024)
  • Blackstone Holdings II L.P. Filed SC 13D/A on LUMOS PHARMA, INC., latest Nov 29, 2023
  • Daniel Stuart Farb Filed SC 13D/A on LUMOS PHARMA, INC., latest Jun 20, 2023 (7 filings since Feb 1, 2022)
  • New Enterprise Associates 14, L.P. Filed SC 13D/A on LUMOS PHARMA, INC., latest Jan 5, 2022
  • LUMOS PHARMA, INC. Austin, Texas
    • BioProtection Systems Corporation Subsidiary · Delaware, United States
    • BlueLink Pharmaceuticals, Inc Subsidiary · Delaware, United States
    • Lumos Pharma Sub, Inc. Subsidiary · Delaware, United States
    • NewLink International Subsidiary · Cayman Islands

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What LUMOS PHARMA, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$05 Dec 31, 2023$53.0K5 Dec 31, 2022−100.0%
Operating-lease assets (leased space)$603.0K5 Dec 31, 2023$230.0K5 Dec 31, 2022+162.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$35.1M5 Dec 31, 2023$56.0M5 Dec 31, 2022−37.4%
Marketable securities, current$999.0K5 Dec 31, 2023$11.4M5 Dec 31, 2022−91.2%
Debt securities available for sale$35.7M5 Dec 31, 2023$66.7M5 Dec 31, 2022−46.4%

Leadership

Who has led LUMOS PHARMA, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Charles J. Link Jr.2011–2019
  2. Richard J. Hawkins2020–2024

Chair

  1. Charles J. Link Jr.2011–2019

President

  1. Nicholas N. Vahanian2011–2019

Chief financial officer

  1. Gordon H. Link Jr.2011–2014
  2. John B. Henneman Iii.2014–2018
  3. Carl W. Langren2018–2021
  4. Lori D. Lawley2021–2024
201520202025
Board members and other officers (26)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • BioProtection Systems Corporation Delaware3
  • BlueLink Pharmaceuticals, Inc Delaware3
  • Lumos Pharma Sub, Inc. Delaware3
  • NewLink International Cayman Islands3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • NEWLINK GENETICS CORPFeb 7, 2002 to Mar 20, 20202

Timeline

  1. Dec 12, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer45
  2. Nov 25, 20248-K Listing notice or transfer; Other events46
  3. Oct 23, 20248-K Entered a material agreement; Results of operations; New debt or obligation47
  4. Aug 1, 20248-K Results of operations48
  5. Jun 5, 20248-K Shareholder vote; Regulation FD disclosure49
  6. May 15, 20248-K Results of operations50
  7. Apr 18, 20248-K Other events51
  8. Mar 20, 20248-K Other events52
  9. Mar 7, 20248-K Results of operations53
  10. Jan 4, 20248-K Regulation FD disclosure54
  11. Nov 15, 20238-K Other events55
  12. Nov 7, 20238-K Other events56
  13. Mar 30, 2020New chief executive Richard J. Hawkins becomes CEO13
  14. Nov 10, 2011New chief executive Charles J. Link Jr. becomes CEO14

Calendar

When it reported results

  1. Oct 23, 2024Reported quarterly or annual results47
  2. Aug 1, 2024Reported quarterly or annual results48
  3. May 15, 2024Reported quarterly or annual results50
  4. Mar 7, 2024Reported quarterly or annual results53
  5. Nov 7, 2023Reported quarterly or annual results57
  6. Aug 9, 2023Reported quarterly or annual results58
  7. May 3, 2023Reported quarterly or annual results59
  8. Mar 1, 2023Reported quarterly or annual results60

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

186 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 34 major events, 79 insider forms, 13 large holders, 46 other. The latest 20:

  1. Feb 13, 2025SCHEDULE 13G/A EDGAR
  2. Dec 23, 202415-12G EDGAR
  3. Dec 13, 2024AW EDGAR
  4. Dec 13, 20244 EDGAR
  5. Dec 13, 20244 EDGAR
  6. Dec 13, 20244 EDGAR
  7. Dec 13, 20244 EDGAR
  8. Dec 13, 20244 EDGAR
  9. Dec 13, 20244 EDGAR
  10. Dec 13, 20244 EDGAR
  11. Dec 13, 20244 EDGAR
  12. Dec 13, 20244 EDGAR
  13. Dec 13, 20244 EDGAR
  14. Dec 13, 20244 EDGAR
  15. Dec 13, 20244 EDGAR
  16. Dec 12, 2024EFFECT EDGAR
  17. Dec 12, 2024EFFECT EDGAR
  18. Dec 12, 2024EFFECT EDGAR
  19. Dec 12, 2024EFFECT EDGAR
  20. Dec 12, 2024EFFECT EDGAR

The 186 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 7 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 6, 2024McKew John C.Chief Scientific OfficerSale3,407$1.89$6.4KForm 4
Apr 3, 2024McKew John C.Chief Scientific OfficerSale2,214$2.78$6.2KForm 4
Feb 6, 2024McKew John C.Chief Scientific OfficerSale438$3.03$1.3KForm 4
Aug 2, 2023McKew John C.Chief Scientific OfficerSale3,407$3.21$10.9KForm 4
Apr 4, 2023McKew John C.Chief Scientific OfficerSale2,214$3.27$7.2KForm 4
Feb 2, 2023McKew John C.Chief Scientific OfficerSale439$3.53$1.6KForm 4
Nov 16, 2022McCracken Joseph SDirectorBuy4,000$5.03$20.1KForm 4
Sep 23, 2022Hawkins Richard JChief Executive OfficerBuy208$8.80$1.8KForm 4
Sep 21, 2022Hawkins Richard JChief Executive OfficerBuy2,214$8.84$19.6KForm 4
Sep 20, 2022Hawkins Richard JChief Executive OfficerBuy1,506$8.75$13.2KForm 4
Sep 19, 2022Hawkins Richard JChief Executive OfficerBuy541$8.65$4.7KForm 4
Aug 25, 2022Raffin Thomas A.DirectorBuy1,150$8.46$9.7KForm 4
Aug 25, 2022McCracken Joseph SDirectorBuy3,170$8.60$27.3KForm 4
Aug 2, 2022McKew John C.Chief Scientific OfficerSale3,407$8.11$27.6KForm 4
Jun 6, 2022McKew John C.Chief Scientific OfficerSale169$7.62$1.3KForm 4
Apr 5, 2022McKew John C.Chief Scientific OfficerSale2,214$8.32$18.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How LUMOS PHARMA, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLUMOS PHARMA, INC.1
  • CIK0001126234
  • Employer ID (EIN)42-14913501
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4200 Marathon Blvd., Suite 200, Austin, TX 787561
  • Phone512-215-26301
  • Shares outstanding8,648,618 as of Nov 5, 202411
  • Public float$21.5M as of Jun 30, 202366
  • On EDGAR sinceFeb 7, 20021
  • Filings1,020 in all: 4 (385), 8-K (247), SC 13G/A (41), 10-Q (40), 3 (32), CT ORDER (20), DEFA14A (20), CORRESP (18)1
    All 58 form types

    UPLOAD (17), SC 13G (15), 10-K (13), DEF 14A (13), 4/A (12), 5 (12), EFFECT (11), 424B5 (9), SC 13D/A (8), S-1/A (7), S-8 (7), S-8 POS (7), POS AM (6), REGDEX (6), S-3 (6), 10-K/A (5), 8-K/A (5), SC 13D (5), 10-Q/A (4), D (4), D/A (4), 3/A (3), PRER14A (3), SCHEDULE 13G/A (3), 144 (2), ARS (2), PRE 14A (2), SC 14D9/A (2), SC TO-I/A (2), SC TO-T/A (2), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 8-A12B (1), AW (1), CERTNAS (1), DEFM14A (1), DEFR14A (1), DFAN14A (1), FWP (1), PREM14A (1), REGDEX/A (1), RW (1), S-1 (1), S-3/A (1), SC 14D9 (1), SC TO-I (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 7, 2024
    Quarterly report (10-Q) Nov 7, 2024
    Proxy statement (DEF 14A) Apr 12, 2024
    Latest 8-K (8-K) Dec 12, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
    SEC EDGAROther events
  56. 56
    SEC EDGAROther events
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66